- Context Therapeutics press release (NASDAQ:CNTX): Net loss of $24.0 million for 2023, as compared to $14.8 million for the same period in 2022.
- Research and development expenses were $17.8 million for 2023, as compared to $7.1 million for the same period in 2022.
- Cash and cash equivalents were $14.4 million at December 31, 2023, compared to $35.5 million at December 31, 2022.
- The company expects its cash and cash equivalents will be sufficient to fund its operations into late 2024.
Context Therapeutics reports FY results
Recommended For You
More Trending News
About CNTX Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| CNTX | - | - |
| Context Therapeutics Inc. | ||